Zusammenfassung
In der vorliegenden Studie sollten alterskorrigierte empirische genetische Belastungsziffern für die Verwandten ersten Grades (Eltern, Geschwister, Kinder) von Typ I-Diabetikern berechnet werden. Diese Risikoziffern sind wichtig für die genetische Beratung und für genetische Modelle des Typ I-Diabetes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Köbberling J, Brüggeboes B (1980) Prevalence of diabetes among children of insulin-dependent diabetic mothers. Diabetologia 18: 459–462
Köbberling J, Tillil H (1982) Empirical risk figures for first degree relatives of non-insulin dependent diabetics. In: Köbberling J, Tattersall R (eds) The genetics of diabetes mellitus. Academic Press, London New York, p 203
Gamble DR, Taylor KW (1969) Seasonal incidence of diabetes mellitus. Br Med J 3: 631–633
Darlow JM, Smith Ch, Duncan LJP (1973) A statistical and genetical study of diabetes. III. Empiric risk to relatives. Ann Hum Genet 37: 157–174
Spielman RS, Baker L, Zmijewski, ChM (1980) Gene dosage and susceptibility to insulin dependent diabetes. Ann Hum Genet 44: 135–150
Cudworth AG, Wolf E (1982) The genetic susceptibility to type I (insulin-dependent) diabetes mellitus. Clin Endocrinol Metab 11: 389–408
Literatur
Brocks D (Persönliche Mitteilung)
Brownlee M, Spiro RG (1979) Glomerular basement membrane metabolism in the diabetic rat in vivo studies. Diabetes 28: 121–125
Hasslacher Ch, Kopischke HG, Bürklin E, Gechter F, Reichenbacher R (1982) In vivo studies on basement membrane synthesis in diabetic and nondiabetic rats. Res Exp Med 181: 245–251
Romen W, Heck T, Rauscher G, Lange HU, Hempel K (1980) Glomerular basement membrane turnover in young, old, and streptozotocindiabetic rats. Renal Physiol (Basel) 3: 324–329
Timpl R, Wiedemann H, van Delden V, Furthmayr H, Kühn K (1981) A network model for the organization of Type IV collagen molecules in basement membranes. Eur J Biochem 120: 203–211
Literatur
Andreani D, DiMario U, Lavicoli M, Pozzilli P, Lumbrosco B, Guy U, Irvine WJ (1978) Immune complexes and diabetic retinopathy. Diabetologia 15: 215–218
Belfiore F, Napoli E, Vecchio LL 1972) Serum N-acetyl-beta-glucosaminidase activity in diabetic patients. Diabetes 21: 1168–1172
Miller B, Keyes FP, Curreri PW (1966) Increase of serum beta-glucuronidase activity in human diabetes mellitus. JAMA 195: 127–130
Pitkänen E, Kyllästinen M, Koivula T, Hormila P (1980) Beta-N-acetylglucosaminidase and beta-glucuronidase activities in insulin-dependent diabetic subjects with retinopathy. Diabetologia 18: 275–278
Whiting W, Ross IS, Borthwick L (1979) Serum and urine N-acetyl-beta-D-glucosaminidase in diabetics on diagnosis and subsequent treatment in insulin dependent diabetics. Clin Chim Acta 92: 459–463
Dance N, Price RG, Cattell WR, Landsell J, Richards B (1970) The excretion of N-acetyl-beta-glucosaminidase and beta-galactosidase by patients with renal disease. Clin Chim Acta 27: 87–92
Fushimi H, Tarui S (1974) Kidney and serum N-acetylglucosaminidase activities in streptozotocin diabetic rats and their responses to insulin and glucagon. J Biochem 76: 225–227
Literatur
Liebich HM, Pickert A, Stierle U, Wöll J (1980) Gas chromatography — mass spectrometry of saturated and unsaturated dicarboxylic acids in urine. J Chromatogr 199: 181–189
Liebich HM, Al-Babbili O (1975) Gas chromatographic — mass spectrometric study of volatile organic metabolites in urines of patients with diabetes mellitus. J Chromatogr 112: 539–550
Literatur
Colwell JA, Lopes-Virella M, Halushka PV (1981) Pathogenesis of atherosclerosis in diabetes mellitus. Diabetes Care 4: 121–133
Steiner G (1981) Diabetes and atherosclerosis: an overview. Diabetes (Suppl 2) 30: 1–7
Tunbridge WMG (1981) Factors contributing to deaths of diabetics under fifty Years of age. Lancet 2: 569–572
Janka HU (1983) Pathogenetische Faktoren für die Atherosklerose bei Diabetikern. Aktuel Endokr Stoffw 4: 9–15
Garcia MJ, McNamara PM, Gordon T, Kannel WB (1974) Morbidity and mortality in diabetics in the Framingham population. Diabetes 23: 105–111
Janka HU, Standl E, Mehnert H (1980) Peripheral vascular disease in diabetes mellitus and its relation to cardiovascular risk factors: Screening with the Doppler ultrasonic technique. Diabetes Care 3: 207–213
Janka HU, Grünwald P, Waldmann G, Standl E, Mehnert H (1982) Das Ruhe-EKG als Indikator für Gefäßveränderungen beim Diabetiker. Med Klin 77: 219–223
Janka HU, Grünwald P, Waldmann G, Standl E, Mehnert H (1982) Karotisstenosen, kardiovaskuläres Risikoprofil und assoziierte Makroangiopathie bei ambulanten Diabetikern: Die Schwabinger Studie zur Makroangiopathie bei Diabetikern. Vasa 11: 111 – 116
Literatur
Berger H, Cicmir I, Grüneklee D, Gries FA (1981) Kardiovaskuläre Reflexstörungen und Pupillenstörungen bei autonomer diabetischer Neuropathie. Aktuel Neurol 1: 7–13
Cicmir I, Berger H, Gries FA (1983) Die diabetische Polyneuropathie. Dtsch Ärztebl (im Druck)
Cicmir I, Grüneklee D, Morguet A, Berger H, Kley HK, Lehmacher W, Gries FA (1980) Studies of heart oscillation in diabetics at rest. In: Gries FA, Freund HJ, Rabe F, Berger H (eds) Aspects of autonomic neuropathy in diabetes. Horm Metab Res (Suppl) 9: 73–76
Grüneklee D, Cicmir I, Morguet A, Wendel V, Bremer HJ (1981) Studies of beat-to-beat heart rate variation in resting diabetic children. In: Weber B (ed) Diabetic angiopathy in children. Karger, Basel, pp 255–259
Morguet A, Springer HJ (1981) Microcomputer-based measurement of beat-to-beat intervals and analysis of heart rate variability. Med Prog Technol 8: 77–82
Literatur
Pickup JC, Bilous RW, Viberti GC, Keen H, Jarret RJ, Glynne A, Cauldwell J, Root M, Rubenstein AH (1982) Plasma insulin and C-peptide after subcutaneous and intravenous administration of human insulin (recombinant DNA) and purified porcine insulin in healthy men. Diabetes Care (Suppl 2) 5: 29–34
Kemmer FW, Sonnenberg G, Cüppers HJ, Berger M (1982) Absorption kinetics of semisynthetic human insulin and biosynthetic (recombinant DNA) human insulin. Diabetes Care (Suppl 2) 5: 23–28
Galloway JA, Root MA, Bergstrom R, Spradlin CT, Howley DC, Fineberg SE, Jackson RL (1982) Clinical pharmacologic studies with human insulin (recombinant DNA). Diabetes Care (Suppl 2) 5: 13–22
Bottermann P, Gyaram H, Wahl K, Ermler R, Lebender A (1982) Insulin concentrations and time-action profiles of three different intermediate-acting insulin preparations in nondiabetic volunteers under glucose-controlled glucose infusion technique. Diabetes Care (Suppl 3) 5: 43–52
Schlüter KJ, Enzmann F, Kerp L (1983) Different potencies of biosynthetic human and purified porcine insulin. Horm Metab Res 15: 271–274
Müller R, Keller U, Berger W (1982) Comparison of semisynthetic and porcine insulin in man. J Clin Invest 12: 281
Klier M, Kerner W, Torres AA, Pfeiffer EF (1981) Comparison of the biologic activity of biosynthetic human insulin in juvenile-onset diabetic subjects assessed by the glucose controlled insulin infusion system. Diabetes Care 4: 193–196
Schlüter KJ, Petersen K-G, Sontheimer J, Enzmann F, Kerp L (1982) Different counterregulatory response to human insulin (recombinant DNA) and purified pork insulin. Diabetes Care (Suppl 2) 5: 78–81
Rosak C, Althoff P-H, Enzmann F, Schöffling K (1982) Comparative studies on intermediary metabolism and hormonal counterregulation following human insulin (recombinant DNA) and purified pork insulin in man. Diabetes Care (Suppl 2) 5: 82–89
Raptis S, Karaiskos C, Enzmann F, Hatzidakis D, Zoupas C, Souvatzoglou A, Diamantopoulos E, Moulopoulos S (1982) Biologic activities of biosynthetic human insulin in healthy volunteers and insulin-dependent diabetic patients monitored by the artificial endocrine pancreas. Diabetes Care 4: 155–159
Kerp L, Steinhilber S, Kasemir H (1966) Ein Verfahren zum Nachweis insulinbindender Antikörper durch Differentialadsorption. Klin Wochenschr 44: 560–567
Literatur
Christiansen AH (1973) Radioimmunoelectrophoresis in the determination of insulin binding to IgG. Methodological studies. Horm Metab Res 5: 147–154
Federlin K, Velčovsky H-G (1974) IgE-Antikörper bei Patienten mit Insulinallergie. Verh Dtsch Ges Inn Med 80: 1613–1617
Fireman P, Fineberg S-E, Galloway JA (1982) Development of IgE antibodies to human (recombinant DNA), porcine and bovine insulins in diabetic subjects. Diabetes Care (Suppl 2) 5: 119–125
Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ (1982) Immunologic improvement resulting from the transfer of animal insulintreated diabetic subjects to human insulin (recombinant DNA). Diabetes Care (Suppl 2) 5: 107–113
Hamilton RG, Rendell M, Adkinson NF (1980) Serological analysis of human IgG and IgE anti-insulin antibodies by solid-phase radioimmunoassays. J Lab Clin Med 96: 1022–1036
Kumar D (1981) Insulin allergy: Differences in the binding of porcine, bovine and human insulins with anti-insulin IgE. Diabetes Care 4: 104–107
Schlüter KJ, Kerp L (1982) Receptor binding studies and clinical effects of human insulin (recombinant DNA): Studies in patients with newly diagnosed typ I diabetes, typ II diabetes, insulin resistance (type A and type B), insulin antibodies, insulin allergy and “Brittle” diabetes. Diabetes Care (Suppl 2) 5: 152–160
Velčovsky HG, Federlin K (1982) Insulin-specific IgG and IgE antibody response in typ I diabetic subjects exclusively treated with human insulin (recombinant DNA). Diabetes Care (Suppl 2) 5: 126–128
Literatur
Beischer W, Keller L, Maas M, Schiefer M, Pfeiffer EF (1976) Human C-peptide, part I: Radioimmunoassay. Klin Wochenschr 54: 709–716
Dole VP, Meinertz H (1960) Microdetermination of long chain fatty acids in plasma and tissues. J Biol Chem 235: 2595–2607
Gerich JE, Langlois M, Noacco C, Karam JH, Fosham PH (1973) Lack of glucagon response to hypoglycemia diabetes: evidence for an intrinsic pancreatic alpha-cell defect. Science 182: 171–173
Hauff C, Sundermann S, Cüppers HJ, Broermann C, Schütte M, Berger M (1981) Absorptionskinetik und biologische Aktivität von semisynthetischem Humaninsulin. Wien Med Wochenschr 121: 10
Heding L (1971) Radioimmunological determination of pancreas and gut glucagon in plasma. Diabetologia 7: 10–19
Klier M, Kerner W, Torres AA, Pfeiffer EF (1981) Comparison of the biologic activity of biosynthetic human insulin and natural pork insulin in juvenile-onset diabetic subjects assessed by the glucose controlled insulin infusion system. Diabetes Care
Mackrell DJ, Sokal JE (1969) Antagonism between effects of insulin and glucagon on the isolated liver. Diabetes Care 18: 724–732
Raptis S, Hadjidakis D, Enzmann F, Raptis A, Diamantopoulos E, Rosenthal J (1982) Inhibition of pancreatic glucagon responses to arginine by human insulin (recombinant DNA) and purified porcine insulin in normal and diabetic subjects. Diabetes Care 5: 93–101
Raptis S, Rosenthal J, Welzel D, Moulopoulos S (1981) Effects of cardioselective and non-cardioselective beta-blockade adrenaline-induced metabolic and cardiovascular responses in man. Eur J Clin Pharmacol 20: 17–22
Rosak CH (1982) Hormonal and metabolic regulation following purified pork insulin and human insulin. Diabetes Care 5: 82–89
Schmidt F (1971) Methoden der Harn- und Blutzuckerbestimmung. Hexokinase G-6-PDH-Verfahren. In: Pfeiffer EF (Hrsg) Handbuch des Diabetes mellitus, Bd 2. Lehmann, München, S 936–946
Thompson JC, Reeder DD, Bunchman HH, Becker HD, Brandt EN (1972) Effect of secretion on circulation gastrin. Ann Surg 176: 384–390
Unger RH (1971) Glucagon physiology and pathophysiology. N Engl J Med 285: 443–449
Literatur
Rüdiger HW, Dreyer M, Kühnau J, Bartelheimer H (1983) Familial insulin resistant diabetes secondary to an affinity defect of the insulin receptor. Hum Gen (im Druck)
Literatur
Bennett T, Farquhar I, Hosking D, Hampton J (1978) Diabetes 27: 1165
Campbell IW et al. (1976) Lancet
Clarke BF, Ewing DJ, Campbell IW (1979) Diabetologia 17: 195–212
Ewing DJ, Campbell IW, Clarke BF (1976) Lancet
Fraser DM, Campbell IW, Ewing DJ, Murray A, Neilson JMM, Clarke BF (1977) Diabetes 26
Hosking DJ, Bennett T, Hampton JR (1978) Diabetes 27
Hreidarsson AB (1981) Diabetologia 20: 475–481
Irsigler et al. (1983) 2. ISGIID-Symposium, Januar 1983
Mencer M (1953) Lancet
Page M, Watkins PJ (1978) Lancet
Sachse et al. (1983) 2. EASD-Pumpen-Symposium, Februar 1983, Igls/Austria
Sachse et al. (1982) Verh Dtsch Ges Inn Med 88: 821–824
Scott J, Lloyd-Mostyn RH (1976) Lancet
Sundkvist GG, Aimer L-O, Liljy B (1979) Med J 7: 924–925
Literatur
Beck-Nielsen H, Pedersen O, Kragballe K, Sorensen NS (1977) The monocyte as a model for the study of insulin receptors in man. Diabetologia 13: 563–569
Schlichtkrull O (1967) The M-value, a new index of blood glucose fluctuations. Acta Med Scand 13
Pedersen O, Beck-Nielsen H, Heding I (1978) Insulin receptor on monocytes from patients with ketosis-prone diabetes mellitus. Diabetes 27: 1098–1104
Fantus G, Ryan J, Gorden P The insulin receptor in insulin-dependent diabetes mellitus: An in vivo and in vitro study. Metabolism 30: 510–517
Misbin RI, Pulkinnen AJ, Lofton SA et al. (1978) Ketoacidosis and the insulin receptor. Diabetes 27: 539–542
Pedersen O, Beck-Nielsen H, Heding L (1980) Increased insulin receptors after exercise in patients with insulin-dependent diabetes mellitus. N Engl J Med 302: 886–892
DeFronzo R, Hendler R, Simonson D (1982) Insulin resistance is a prominent feature of insulin dependent diabetes. Diabetes 31: 795–801
Literatur
Berger M, Sonnenberg GE, Chantelau E (1982) Insulin pump treatment for diabetes: some questions can be answered already. Clin Physiol 2: 111
Brownlee M, Cahill GF (1979) Diabetic control and vascular complications. Atherosclerosis Rev 4: 29
Flückiger R, Winterhalter KH (1976) In vitro synthesis of hemoglobin A1c. FEBS Lett 71: 356
Pickup JC, Keen H, Parsons JA, Alberti KGMM (1978) Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1: 204
Raskin P, UNger RH (1978) Effect of insulin therapy on the profiles of plasma immunoreactive glucagon in juvenile-type and adult-type diabetics. Diabetes 27: 411
Siperstein MD, Norton W, Unger RH, Madison LL (1966) Muscle capillary basement membrane width in normal, diabetic and prediabetic patients. Trans Assoc Am Physicians 79: 330
Siperstein MD, Foster DW, Knowles HC, Madison LL, Roth J (1977) Control of blood glucose and diabetic vascular disease. N Engl J Med 296: 1060
Sonnenberg GE, Chantelau E, Berger M (1981) Ein neues therapeutisches Prinzip in der Diabetologie: kontinuierliche Insulin-Infusion mittels portabler Pumpen. Dtsch Med Wochenschr 106: 891
Sonnenberg GE, Chantelau E, Berger M (1982) Routine treatment of insulin-dependent diabetes mellitus with continuous subcutaneous insulin infusion. In: Skyler JS (ed) Insulin update 1982. Excerpta Medica, p 223
Literatur
Blackshear PJ, Rohde TD, Prosi F, Buchwald H (1979) The implantable pump: A new concept of drug delivery. Med Prog Technol 6: 149–161
Buchwald H, Rohde TD, Schneider PD, Varco RL, Blackshear PJ (1980) Long-term, continuous intravenous heparin administration by an implantable pump in ambulatory patients with recurrent venous thrombosis. Surgery 88: 507–516
Irsigler K, Kritz H (1979) Long-term continuous insulin therapy with a portable insulin dosage-regulating apparatus. Diabetes 28: 196–203
Pietri A, Ehle A, Raskin P (1980) Changes in nerve conduction velocity after six weeks of glucoregulation with portable insulin infusion pumps. Diabetes 29: 668–671
Schlichtkrull J, Munk O, Jersild M (1965) The M-value, an index of blood sugar control in diabetes. Acta Med Scand 177: 95–102
Schulz G, Beyer J, Strack T, Krause U, Nagel J, Cordes U, Weber T (1982) Die Entwicklung von Insulininfusionsprofilen zur Therapie insulinpflichtiger Diabetiker mit tragbaren Insulininfusionssystemen. Biomed Tech (Berlin) 27: 203–208
Literatur
Boulton AJ, Drury J, Clarke B, Ward JD (1982) Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 5: 386–390
Kashiwagi S, Schottenfeld Y, Kessler C, Schreiber S, Grodtke N, Gries FA (1982) Technical problems and complications of treatment with continuous insulin infusion systems. Diabetologia 23: 178–179
Hamet P, Abarca G, Lopez D, Hamet M, Bourque M, Peyronnard JM, Charron L, Larochelle P (1982) Patient self-management of continuous subcutaneous insulin infusion. Diabetes Care 5: 485–491
Hooymans JMM, Ballegooie EV, Schweitzer NM, Doorenbos H, Reitsma WD, Sluiter WJ (1982) Worsening of diabetic retinopathy with strict control of blood sugar. Lancet 2: 428
Irsigler K, Kritz H, Najemnik C, Freyler H (1980) Rückbildung einer floriden proliferativen diabetischen Retinopathie durch 5 Monate lang dauernde Normoglykämie mittels eines tragbaren Insulindosiergerätes. Wien Klin Wochenschr 8: 270–276
Irsigler K, Kritz H (1983) Neue Wege in der Diabetestherapie, extern tragbare und implantierbare Insulindosiergeräte. Internistische Welt 2: 37–50
Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T (1983) Effect of 1 Year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet 1: 200–204
Mecklenburg RS, Benson JW, Becker NM, Brazel PL, Fredlund PN, Metz RJ, Nielsen RL, Sannar CA, Steenrod WJ (1982) Clinical use of the insulin infusion pump in 100 patients with type I diabetes. N Engl J Med 307: 513–518
Pickup JC, White MC, Keen H, Parsons JA, Alberti KGMM (1979) Long-term continuous subcutaneous insulin infusion in diabetics at home. Lancet 2: 870–873
Pietri A, Ehle AL, Raskin P (1980) Changes in nerve conduction velocity after six weeks of glucoregulation with portable insulin infusion pumps. Diabetes 29: 668–671
Raskin P (1982) Treatment of type I diabetes with portable insulin infusion devices. Diabetes Care (Supp1 1) 5: 48–52
Schiffrin A, Colle E, Belmonte MM (1982) Improved control in diabetes with continuous subcutaneous insulin infusion. Diabetes Care 3: 643–647
Skyler JS, Alberti KGMM (1980) Clinical assessment of metabolic control in insulin-dependent diabetes mellitus. Diabetes Care 3: 369–370
White MC, Kohner EM, Pickup JC, Keen H (1981) Reversal of diabetic retinopathy by continuous subcutaneous insulin infusion: a case report. Br J Ophthalmol 65: 307–311
Literatur
Grodsky GM, Epstein GH, Fanska R, Karam JH (1977) Pancreatic action of the sulfonylureas. Fed Proc 36: 2714–2719
Lunetta M, Leonardi S, Rapisarda, S, Mughini L (1981) Effects of short and longterm glibenclamide treatment of the response of pancreatic alpha and beta cells to oral glucose loading in adult-onset diabetes. Curr Ther Res 30: 50–59
Feldman JM, Lebovitz HE (1971) Endocrine and metabolic effects of glibenclamide: evidence for an extrapancreatic mechanism of action. Diabetes 20: 745–755
Beck-Nielsen H, Pedersen O, Lindskow HO (1979) Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide. Acta Endocrinol 90: 451–462
Olefsky JM, Reaven GM (1976) Effects of sulfonylurea therapy on insulin binding to mononuclear leukocytes of diabetic patients. Am J Med 60: 89–95
Bachmann W, Böttger I, Haslbeck M, Mehnert H (1979) Extrapancreatic action of sulfonylureas: effect of gliquidone on insulin and glucagon binding to rat liver plasma membranes. Eur J Clin Invest 9: 411–415
Feinglos MN, Lebovitz HE (1978) Sulfonylureas increase the number of insulin receptors. Nature 276: 184–185
Prince MJ, Olefsky JM (1980) Direct in vivo effect of a sulfonylurea to increase human fibroblast insulin receptors. J Clin Invest 66: 608–611
Salhanick AJ, Konowitz P, Amatruda JM (1982) Potentiation of insulin sensitive lipogenesis by a sulfonylurea in rat hepatocytes. Diabetes (Suppl 2) 31: 213/54A
Maloff BL, Lockwood DH (1981) In vitro effects of a sulfonylurea on insulin action in adipocytes. J Clin Invest 68: 85–90
Berry MN, Friend DS (1969) High-yield preparation of isolated rat liver parenchymal cells. J Cell Biol 43: 506–520
Bernaert D, Wanson JC, Drochmans P, Popowski A (1977) Effect on insulin on ultrastructure and glycogenesis in primary cultures of adult rat hepatocytes. J Cell Biol 74: 878–900
Joost HG, Arend W, Holze SA (1982) Effects of tolbutamide on insulin binding to isolated cells of the rat. Biochem Pharmacol 31: 1227–1231
Vigneri R, Pezzino V, Iwamoto Y, Wong KY, Polosa P, Goldfine ID (1981) In vitro effects of oral hypoglycemic agents on the binding of 125I-insulin to cultured cells. In: Andreani D, DePirro R (eds) Serono Symposium, N 41. Academic Press, London New York
Hepp KD, Langley J, Funcke HJ v, Renner R, Kemmler W (1975) Increased insulin binding capacity of liver membranes from diabetic Chinese hamsters. Nature 258: 154
Literatur
Berger M, Berchtold P (1979) Beta-Rezeptorenblocker. Dtsch Med Wochenschr 104: 888–893
Wollf HP (1977) Hypoglykämie durch β-Rezeptoren-Blocker? Dtsch Med Wochenschr 102: 330–1335
Patsch W, Patsch JR, Sailer S (1977) Untersuchung zur Wirkung von Pindolol auf Kohlenhydrat- und Fettstoffwechsel bei Diabetes mellitus. Int J Clin Pharmacol 15: 394– 398
Schlierf G, Papanberg J, Raetzer H (1973) The effect of 1-(indol-4-yloxy)-3-isopropylamino-propan-2-ol (LB-46, Visken) on carbohydrate and lipid metabolism. Eur J Clin Pharmacol 5: 154–160
Raptis S, Karaiskos K, Hatzidakis D, Zoupas Ch, Diamantopoulos E, Moulopoulos S (1982) Comparison of glycemic and metabolic control in diabetics, achieved by an artificial endocrine pancreas versus an open loop intravenous delivery system 12: 277–286
Pfeiffer EF (1982) The artificial endocrine pancreas (AEP): Past, presence and future
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 J. F. Bergmann Verlag, München
About this paper
Cite this paper
Tillil, H. et al. (1983). Diabetes. In: Schlegel, B. (eds) Verhandlungen der Deutschen Gesellschaft für innere Medizin. Verhandlungen der Deutschen Gesellschaft für innere Medizin, vol 89. J.F. Bergmann-Verlag. https://doi.org/10.1007/978-3-642-85456-9_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-85456-9_15
Publisher Name: J.F. Bergmann-Verlag
Print ISBN: 978-3-8070-0335-1
Online ISBN: 978-3-642-85456-9
eBook Packages: Springer Book Archive